Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker BEFREE <b>Conclusions:</b> KRAS-mutant pancreatic cancer cells can activate PSCs through PAI-1/LRP-1 signaling to promote fibrosis and cancer progression. 31695760

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker BEFREE K-RAS, C-MYC and C-ERBB2 are protooncogenes taking part in carcinogenesis and tumor progression in the colon. 15493579

2004

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE KRAS mutation is very strongly associated with a villous architecture and through villous component expansion, KRAS mutations may increase risk of tumor progression in sporadic colorectal polypoid adenomas. 22729813

2012

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE K-RAS mutations have a role in tumor development as well as in tumor progression and resistance. 24138715

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE KRAS mutation in colorectal cancer (CRC) activates transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1) to promote tumor progression. 25524577

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression BEFREE KRAS-specific IgG may, therefore, serve as a readout of the activation of both arms of the anti-tumor adaptive immune armament although some B-cell populations may promote tumor progression. 30283732

2018

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker BEFREE KRAS status may influence the host immune response against tumor progression. 31834556

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker BEFREE Accordingly, administration of the JAK1/2 selective tyrosine kinase inhibitor ruxolitinib reduced proliferation of tumor cells and effectively reduced tumor progression in immunodeficient and immunocompetent mouse models of K-RAS-driven lung AC. 31407334

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE Activating KRAS mutation almost always drives pancreatic tumour initiation, however, deregulation of other potentially druggable pathways promotes tumour progression. 24717934

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE Among the low-grade serous carcinomas, there is a high frequency of activating mutations in the KRAS or BRAF genes; however, it remains unclear as to how these mutations contribute to tumor progression. 27128903

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE As identical KRAS mutations were present in low-grade and higher-grade areas in individual cases, KRAS mutations occurring in low-grade MCNs may lead to tumour progression. 28570009

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE Besides, mutations of K-ras gene have also been proven to play an important role in human tumor progression. 19450806

2009

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE Data on the presence of mutations in KRAS gene in CRC and its relationship with clinicopathological parameters and expression of genes involved in tumor progression are scarce. 26749281

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE Despite some evidence that KRAS mutation status affects cancer progression, a consensus is yet to be reached. 30711927

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. 24803537

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE Few reports addressed the association between KRAS-BRAF mutations and tumour progression specifically in sporadic microsatellite-stable (MSS) CRC. 16953233

2007

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE Finally, inhibition of EGFR and c-RAF expression effectively blocked tumor progression in nine independent patient-derived xenografts carrying KRAS and TP53 mutations. 30975481

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker BEFREE Here we identify cancer cell-expressed murine TRAIL-R, whose main function ascribed so far has been the induction of apoptosis as a crucial mediator of KRAS-driven cancer progression, invasion, and metastasis and in vivo Rac-1 activation. 25843002

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE High frequent G>T transversions in APC and KRAS2 (mutated in early tumour development) but not in P53 and SMAD4 (implicated in tumour progression) might indicate a predominant MUTYH effect in early carcinogenesis. 19527492

2009

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE However, continued requirement of Wnt/β-catenin signaling for tumor progression in the context of acquired KRAS and other mutations is less well-established. 23539443

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 GeneticVariation BEFREE In contrast to deficient MMR (dMMR) CRC, data on the presence of KRAS oncogenic mutations in proficient MMR (pMMR) CRC and their relationship with tumor progression are scarce. 26042813

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker BEFREE In several KRAS-driven mouse models, both the loss of TGF-β signaling and elevated β1-integrin mechanosignaling engaged a positive feedback loop whereby STAT3 signaling promotes tumor progression by increasing matricellular fibrosis and tissue tension. 27089513

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker BEFREE In this review, we will introduce cellular plasticity and its effect on cancer progression and therapy resistance and then summarize the drivers of EMT with an emphasis on KRAS effector signaling. 31681587

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker BEFREE It also seems to be a critical issue whether the K-RAS testing must be done on primary, regional or distant metastatic tissues: data already suggest a small but significant chance of alteration during tumor progression. 20718705

2010

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker BEFREE Mutation in K-RAS (K-RAS-MT) plays important roles in both cancer progression and resistance to anti-epidermal growth factor receptor (EGFR) therapy in gastrointestinal tumors. 27312358

2017